EOM Pharmaceuticals Holdings (IMUC) Stock Overview
A clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IMUC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
EOM Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$0.34 |
| 52 Week Low | US$0.036 |
| Beta | 0 |
| 1 Month Change | 6.60% |
| 3 Month Change | 8.04% |
| 1 Year Change | 3.16% |
| 3 Year Change | -54.31% |
| 5 Year Change | n/a |
| Change since IPO | -68.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMUC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | -2.8% | -1.9% |
| 1Y | 3.2% | 21.2% | 14.9% |
Return vs Industry: IMUC underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: IMUC underperformed the US Market which returned 16.5% over the past year.
Price Volatility
| IMUC volatility | |
|---|---|
| IMUC Average Weekly Movement | 114.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IMUC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IMUC's weekly volatility has increased from 83% to 114% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Irach Taraporewala | eompharma.com |
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion.
EOM Pharmaceuticals Holdings, Inc. Fundamentals Summary
| IMUC fundamental statistics | |
|---|---|
| Market cap | US$20.23m |
| Earnings (TTM) | -US$5.13m |
| Revenue (TTM) | n/a |
Is IMUC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMUC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.13m |
| Earnings | -US$5.13m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IMUC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/21 08:59 |
| End of Day Share Price | 2026/03/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EOM Pharmaceuticals Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.